|
Accenture & BMS form Indian pharmacovigilance centre |
| Accenture and Bristol-Myers Squibb have formed a pharmacovigilance centre in Chennai, India. It is the first joint centre for adverse event report processing, medical review and reporting (2007-10-11) |
|
| Covance builds new US pre-clinical laboratory |
| Covance (Princeton, New Jersey) has purchased from Eli Lilly a partially constructed insulin manufacturing facility on a 47-acre site in Prince William County's technology park (Virginia, US). (2007-12-04) |
|
|
PPD expands Indian business |
| PPD (Wilmington, North Carolina) has appointed Dr Philip Mathew as director of strategic development, to lead its Phase II-IV operations and expansion in India. (2008-01-02) |
|
| GCT sets up Romanian office |
| Global Clinical Trials (Princeton, New Jersey), which conducts clinical trials in the former USSR and Eastern Europe, has opened a new office in Bucharest, Romania. (2008-01-02) |
|
|
French ophthalmology CROs merge |
| Two French CROs specialising in ophthalmology, Iris Pharma and Clirophtha, have merged. The combined company will be known as Iris Pharma (2008-01-04) |
|
| Chiltern acquires US CRO CTMS |
| UK CRO Chiltern International (Slough, Berkshire) has acquired the independent US CRO Clinical Trial Management Services. Terms were not disclosed. (2007-11-26) |
|
|
Quintiles expands Chinese facilities |
| Quintiles Transnational (Research Triangle Park, North Carolina) is to expand its global central laboratories and clinical development service (CDS) units in Beijing, China. (2008-01-16) |
|
| Merck & Newron start Phase III safinamide trial |
| Merck KGaA’s Merck Serono division and Newron Pharmaceuticals (Milan, Italy) have launched a Phase III trial of safinamide as an add-on to dopamine agonist therapy in early Parkinson’s disease. (2007-12-06) |
|
|
Isotechnika to Isotechnika to monitor long-term use of ISA247monitor long-term use of ISA247 |
| Isotechnika (Edmonton, Canada) has received permission from the US Food and Drug Administration for the long-term use of ISA247 for the prevention of rejection in patients currently participating in i (2007-11-05) |
|
| Indian and German CROs to merge |
| Indian CRO Manipal AcuNova (Bangalore) and its German counterpart ECRON (Frankfurt) have signed a definitive merger agreement. The combined company, ECRON AcuNova, will have 265 employees (2007-11-20) |
|
|
Seattle starts Phase IIb trial of SGN-40 |
| Seattle Genetics (Bothell, Washington) has begun a Phase IIb clinical trial of its monoclonal antibody SGN-40 as an adjunct to second-line therapy for relapsed or refractory diffuse large B-cell lymph (2007-12-10) |
|
| Positive Phase II results for GSK’s malaria vaccine |
| Results from a Phase I/IIb trial of GlaxoSmithKline’s malaria vaccine, Mosquirix (RTS,S/AS02D), published in The Lancet, indicate that it is safe, well tolerated and immunogenic in African infants. (2007-10-22) |
|
|
AstraZeneca signs clinical study deal with Japanese university |
| AstraZeneca’s Osaka-based Japanese subsidiary has reached a master clinical study agreement with Keio University School of Medicine (Shinjuku-ku, Tokyo). Separate contracts on future clinical trials (2007-10-10) |
|
|
TgAAC94 exonerated in US trial death |
| Targeted Genetics (Boston, Massachusetts) says that final tests support earlier indications that a patient death during a trial of its injectable anti-arthritis drug, tgAAC94, was not caused by the dr (2007-11-14) |
|
| Indian & Canadian CROs form joint venture |
| Matrix Group (Hyderabad, India) and ethica Clinical Research (Montreal, Canada) have formed a joint venture, ethicamatrix CRO Pvt Ltd, to manage contract research services in India. (2007-10-10) |
|
|
PRA moves HQ & plans recruitment drive |
| PRA International is to relocate its corporate headquarters from Reston, Virginia, to Raleigh, North Carolina, by the end of 2007. It expects to take a charge of some $1.7 million associated with the (2007-10-10) |
|
| Daiichi Sankyo & Lilly stall two prasugrel trials |
| Daiichi Sankyo and Eli Lilly and have suspended enrolment and administration of the oral antiplatelet agent, prasugrel, in two Phase II studies until protocol amendments can be agreed. (2007-11-05) |
|
|
MDS expands Chinese central labs |
| MDS Pharma Services (King of Prussia, Pennsylvania) has expanded its central lab operations in China, moving to a new, 25,000 sq ft facility near Beijing airport. (2007-11-08) |
|
| Penn sets up US subsidiary |
| UK pharmaceutical development and custom manufacturing specialist Penn Pharmaceutical Services has set up a US subsidiary, Penn Pharmaceutical Services US Inc, in Philadelphia, Pennsylvania. (2007-10-18) |
|
|
RAC concurs with US FDA on tgAAC94 |
| The US National Institutes of Health Recombinant DNA Advisory Committee has concurred with earlier conclusions that a patient death during a trial of Targeted Genetics’ injectable anti-arthritis drug, (2007-12-13) |
|
| Phase Forward acquires Green Mountain Logic |
| Phase Forward (Waltham, Massachusetts), which provides data management systems for clinical trials and drug safety, has acquired privately held Green Mountain Logic for $5.25 million in cash. (2007-11-05) |
|
|
Parexel acquires Taiwanese CRO for $51 million |
| Parexel International (Boston, Massachusetts) has acquired Taiwanese CRO Apex International Clinical Research for T$1.7 billion (US$50.9 million). The acquisition was made by Parexel (Taiwan) Inc, wh (2007-10-18) |
|
| India to host 30% of global clinical research by 2020 |
| India is expected to host 30% of the world's contract research within the next 10-15 years, driven by the attractions of low cost and high quality standards, says the India Brand Equity Foundation, IB (2007-10-22) |
|
|
Russian and Indian CROs form alliance |
| Synergy Research Group (SynRG – Moscow, Russia) has formed an alliance with Neeman Medical International (NMI – New Delhi, India), after five months of negotiation. (2007-10-08) |
|
